GBS Ventures

Total investments

64

Average round size

16M

Portfolio companies

30

Rounds per year

2.37

Lead investments

10

Follow on index

0.53

Exits

11

Stages of investment
Private EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareEnterprise SoftwareMedical DeviceMedicalPharmaceuticalTherapeuticsService IndustryBiopharmaClinical Trials

Summary

GBS Ventures appeared to be the VC, which was created in 1996. The company was established in Australia. The main department of described VC is located in the Melbourne.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the GBS Ventures, startups are often financed by Sofinnova Investments, QIC BioVentures, Prolog Ventures. The meaningful sponsors for the fund in investment in the same round are Uniseed Ventures, Delphi Ventures, Alloy Ventures. In the next rounds fund is usually obtained by Vivo Capital, Uniseed Ventures, Sofinnova Investments.

The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Nuon Therapeutics, NovaSys, CHF Solutions, Inc.. Among the most successful fund investment fields, there are Medical Device, Medical.

Speaking about the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations. The fund is constantly included in 2-6 investment rounds annually. The average startup value when the investment from GBS Ventures is 50-100 millions dollars. The common things for fund are deals in the range of 10 - 50 millions dollars. Opposing the other organizations, this GBS Ventures works on 11 percentage points less the average amount of lead investments. The higher amount of exits for fund were in 2017. The important activity for fund was in 2010.

This organization was formed by Brigitte Smith, Geoff Brooke. We also calculated 2 valuable employees in our database.

Show more

Investments analytics

Analytics

Total investments
64
Lead investments
10
Exits
11
Rounds per year
2.37
Follow on index
0.53
Investments by industry
  • Biotechnology (55)
  • Health Care (44)
  • Medical Device (26)
  • Medical (20)
  • Pharmaceutical (14)
  • Show 17 more
Investments by region
  • United States (48)
  • Australia (13)
  • United Kingdom (3)
Peak activity year
2010

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
19
Avg. valuation at time of investment
40M
Group Appearance index
0.91
Avg. company exit year
16
Avg. multiplicator
2.12

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Moximed 17 Mar 2017 Biotechnology, Health Care, Medical Device Late Stage Venture 50M United States, California, Hayward
PolyGroup 08 Dec 2016 Biotechnology, Medical Device, Life Science, Chemical Seed 125K United States, Indiana, New Albany
Uptake Medical 07 Jul 2010 Biotechnology, Health Care, Medical Early Stage Venture 17M United States, Washington, Seattle
Webacy 01 Jan 2021 Seed 1M

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.